ShareValue scores for FTRE: Valuation 60, Quality 51, Growth 34, Health 28.

Fortrea Holdings Inc. logo

FTRE
NASDAQ

Fortrea Holdings Inc.

$17.69(-7.14%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

3% to 16%
Valuation
60
Fair Value
Price vs Value
Quality
51
Moderate
Business Strength
Growth
34
Weak
Revenue & Earnings
Health
28
Stressed
Financial Stability
Momentum
92
Bullish
Price Trend

Company Details

About

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026